- Ticker
- AKBA
- Price
- 0.98
- Stock movement down
- -0.04 (-3.43%)
- Company name
- Akebia Ther
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 181.48M
- Ent verdi
- 433.51M
- Pris/omsetning
- 0.62
- Pris/bok
- 19.43
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- 278.85%
- 3 års avkastning
- -28.81%
- 5 års avkastning
- -34.17%
- 10 års avkastning
- -
Sist oppdatert: 2023-11-21
Akebia Therapeutics, Inc. (NASDAQ:NASDAQ:AKBA) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ETCompany ParticipantsMercedes Carrasco - Senior...
8. november 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
8. november 2023
iO Charts is a Seeking Alpha partner
UTBYTTE
AKBA betaler ikke utbytte
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
7. november 2023
iO Charts is a Seeking Alpha partner
Akebia Therapeutics is awaiting an FDA decision on Vafseo expected in March 2024, supported by positive post-marketing safety data. Learn more on AKBA stock here.
3. november 2023
iO Charts is a Seeking Alpha partner
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 0.62 |
| Pris til bok | 19.43 |
| EV i forhold til salg | 1.48 |
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
25. oktober 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
28. september 2023
iO Charts is a Seeking Alpha partner
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 184.25M |
| EPS (TTM) | -0.50 |
| FCF per aksje (TTM) | -0.40 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 292.60M |
| Bruttofortjeneste (TTM) | 201.62M |
| Driftsinntekter (TTM) | -85.30M |
| Netto inntekt (TTM) | -92.56M |
| EPS (TTM) | -0.50 |
| EPS (1 år fremover) | -0.25 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 68.90% |
| Driftsmargin (TTM) | -29.15% |
| Fortjenestemargin (TTM) | -31.63% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 90.47M |
| Netto fordringer | 39.18M |
| Samlede omløpsmidler | 90.47M |
| Goodwill | 55.05M |
| Immaterielle eiendeler | 72.08M |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 351.83M |
| Leverandørgjeld | 18.02M |
| Kortsiktig/nåværende langsiktig gjeld | 95.04M |
| Sum kortsiktig gjeld | 124.76M |
| Sum gjeld | 342.49M |
| Aksjonærenes egenkapital | 9.34M |
| Netto varige driftsmidler | -117.80M |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -73.15M |
| Kapitalutgifter (TTM) | 114.00K |
| Fri kontantstrøm (TTM) | -73.15M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -990.82% |
| Avkastning på eiendeler | -26.31% |
| Avkastning på investert kapital | -223.89% |
| Kontantavkastning på investert kapital | -176.95% |
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
26. september 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
28. august 2023
iO Charts is a Seeking Alpha partner
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 1.02 |
| Daglig høy | 1.02 |
| Daglig lav | 0.98 |
| Daglig volum | 676K |
| Tidenes høyeste | 29.17 |
| 1 år analytikerestimat | 1.63 |
| Beta | 0.83 |
| EPS (TTM) | -0.50 |
| Utbytte per aksje | - |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | - |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| AKBA | S&P500 | |
| Nåværende prisfall fra toppnotering | -96.62% | -5.12% |
| Høyeste prisfall | -99.14% | -56.47% |
| Dato for høyeste fall | 29 Nov 2022 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -72.99% | -11.48% |
| Gj.snittlig tid til ny topp | 406 days | 13 days |
| Maks tid til ny topp | 2373 days | 1805 days |
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
25. august 2023
iO Charts is a Seeking Alpha partner
Akebia Therapeutics, Inc. (NASDAQ:NASDAQ:AKBA) Q2 2023 Earnings Conference Call August 25, 2023 9:00 AM ETCompany ParticipantsMercedes Carrasco - Senior...
25. august 2023
iO Charts is a Seeking Alpha partner
SELSKAPSOPPLYSNINGER
Markedsverdi
181.48M
Markedsverdi kategori
Small-cap
Beskrivelse
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Ansatte
204
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
John P. Butler
Land
USA
By
Cambridge
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
24. august 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
24. august 2023
iO Charts is a Seeking Alpha partner
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Seeking AlphaPressemeldinger
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
10. august 2023
Akebia Therapeutics plans to resubmit kidney disease drug application, while its stock outperforms S&P 500 and shows promising growth potential. Read why AKBA is a Hold.
2. august 2023
Akebia Therapeutics is cash poor, has large debt, and its Q2 revenues are unlikely to meet analyst estimates. Read about AKBA's upcoming post-earnings catalysts.
2. august 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
18. juli 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
20. juni 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
13. juni 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
2. juni 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
31. mai 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
30. mai 2023
Akebia Therapeutics' valuation should be at least $716 million, more than 3x its current valuation. Read more to see why I would rate AKBA stock as Strong Buy.
29. mai 2023
iO Charts is a Seeking Alpha partnerNeste side